OPIANT PHARMACEUTICALS, INC. (OTCMKTS:OPNT) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
OPIANT PHARMACEUTICALS, INC. (OTCMKTS:OPNT) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On July 10, 2019, the Board of Directors of Opiant Pharmaceuticals, Inc. (the “Company”) amended and restated the Company’s bylaws (as amended and restated, the “Bylaws”) to:
The foregoing description of the Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Bylaws, which is filed as Exhibit 3.1-K and is incorporated by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
OPIANT PHARMACEUTICALS, INC. Exhibit
EX-3.1 2 opiant-bylaws.htm EXHIBIT 3.1 Exhibit Exhibit 3.1AMENDED AND RESTATEDBYLAWS OFOPIANT PHARMACEUTICALS,…
To view the full exhibit click
EX-3.1 2 opiant-bylaws.htm EXHIBIT 3.1 Exhibit Exhibit 3.1AMENDED AND RESTATEDBYLAWS OFOPIANT PHARMACEUTICALS,…
To view the full exhibit click
hereAbout OPIANT PHARMACEUTICALS, INC. (OTCMKTS:OPNT)
Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.
